ProKidney Corp. (PROK) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 74.87M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $74.87M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $101.89M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $108.54M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $95.32M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $84.94M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $97.81M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $99.12M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $108.09M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $214.51M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $84.39M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $60.65M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $191.39M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $243.55M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $271.63M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $490.25M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $506.33M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $440.49K | (m) | (m) |
| 2021-09-30 | (m) | (m) | $542.30K | (m) | (m) |
| 2021-06-30 | (m) | (m) | $223.54K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.